vedelianin: Cytotoxic; from Macaranga tanarius; structure in first source
vedelianin : A stilbenoid derivative isolated from Macaranga alnifolia and Macaranga alnifolia and has been shown to exhibit cytotoxic activity.
Flora | Rank | Flora Definition | Family | Family Definition |
---|---|---|---|---|
Macaranga | genus | A plant genus. Members contain mappain.[MeSH] | Euphorbiaceae | The spurge family of flowering plants in the order Malpighiales. The family consists of annual and perennial herbs and woody shrubs or trees. Members contain securinine.[MeSH] |
Macaranga alnifolia | species | [no description available] | Euphorbiaceae | The spurge family of flowering plants in the order Malpighiales. The family consists of annual and perennial herbs and woody shrubs or trees. Members contain securinine.[MeSH] |
ID Source | ID |
---|---|
PubMed CID | 643539 |
CHEMBL ID | 223046 |
CHEBI ID | 66352 |
Synonym |
---|
vedelianin |
inchi=1/c29h36o6/c1-16(2)6-9-20-21(30)11-18(12-22(20)31)8-7-17-10-19-14-25-28(3,4)27(34)24(33)15-29(25,5)35-26(19)23(32)13-17/h6-8,10-13,24-25,27,30-34h,9,14-15h2,1-5h3/b8-7+/t24-,25-,27-,29-/m1/s |
nsc720065 |
nsc-720065 |
chebi:66352 , |
CHEMBL223046 |
(2s,3r,4ar,9ar)-7-[(e)-2-[3,5-dihydroxy-4-(3-methylbut-2-enyl)phenyl]ethenyl]-1,1,4a-trimethyl-3,4,9,9a-tetrahydro-2h-xanthene-2,3,5-triol |
2alpha,3alpha-dihydroxy-7-(6'-isoprenyl-5',7'-dihydroxystyryl)1,1-dimethyl-2,3,4,4a,9,9a-hexahydro-1h-xanthene |
(+)-vedelianin |
(2s,3r,4ar,9ar)-7-{(e)-2-[3,5-dihydroxy-4-(3-methylbut-2-en-1-yl)phenyl]ethenyl}-1,1,4a-trimethyl-2,3,4,4a,9,9a-hexahydro-1h-xanthene-2,3,5-triol |
Q27134899 |
Role | Description |
---|---|
antineoplastic agent | A substance that inhibits or prevents the proliferation of neoplasms. |
plant metabolite | Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Class | Description |
---|---|
stilbenoid | Any olefinic compound characterised by a 1,2-diphenylethylene backbone. |
organic heterotricyclic compound | An organic tricyclic compound in which at least one of the rings of the tricyclic skeleton contains one or more heteroatoms. |
resorcinols | Any benzenediol in which the two hydroxy groups are meta to one another. |
cyclic ether | Any ether in which the oxygen atom forms part of a ring. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID293633 | Growth inhibition of NCI60 cells after 48 hrs | 2007 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4 | Total synthesis of (R,R,R)- and (S,S,S)-schweinfurthin F: differences of bioactivity in the enantiomeric series. |
AID1502930 | Antiproliferative activity against human A549 cells after 72 hrs by MTS assay | 2017 | Journal of natural products, 10-27, Volume: 80, Issue:10 | Cytotoxic Prenylated Stilbenes Isolated from Macaranga tanarius. |
AID1502929 | Antiproliferative activity against human U87 cells after 72 hrs by MTS assay | 2017 | Journal of natural products, 10-27, Volume: 80, Issue:10 | Cytotoxic Prenylated Stilbenes Isolated from Macaranga tanarius. |
AID280644 | Antiproliferative activity against drug-sensitive human A2780 cells | 2007 | Journal of natural products, Mar, Volume: 70, Issue:3 | Antiproliferative prenylated stilbenes and flavonoids from Macaranga alnifolia from the Madagascar rainforest. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (40.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.87) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |